Concepedia

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial

Won Seog Kim, Christian Buske, Michinori Ogura, Wojciech Jurczak, Juan‐Manuel Sancho, Edvard Zhavrid, Jin Seok Kim, José‐Ángel Hernández‐Rivas, Aliaksandr Prokharau, Mariana Vasilică,

The Lancet Haematology · 2017 · 75 citations · 14 references

DOIFull text

Open access

Concepts

References

14

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

Donald J. Schuirmann · Journal of Pharmacokinetics and Biopharmaceutics · 1987 · 2.6K citations · Full text

, , +10

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

W. Hiddemann · Blood · 2005 · 1.3K citations · Full text

, , +7

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial

Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations

, , +6

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

R. E. Marcus · Blood · 2004 · 970 citations · Full text

, , +5

Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Barbara Eichhorst, Tadeusz Robak, Emili Montserrat et al. · Annals of Oncology · 2015 · 605 citations

, , +14